Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria

British Journal of DermatologyVolume 183, Issue 6 p. 1124-1126 Research Letter Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria J. Castagna, Corresponding Author castagnajulie@gmail.com orcid.org/0000-0002-9983-9521 Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Contribution: Conceptualization (lead), Data curation (lead), Methodology (lead), Resources (equal), Writing - original draft (lead), Writing - review & editing (lead)Search for more papers by this authorL. Bernard, Hospices Civils de Lyon, Public Health Department, Lyon, France Claude Bernard University Lyon I, Lyon, France Contribution: Formal analysis (lead)Search for more papers by this authorF. Hacard, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Resources (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorF. Delcroix, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Resources (equal), Validation (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorA.-S. Darrigade, Department of Dermatology, Bordeaux University Hospitals, Bordeaux, France Contribution: Resources (equal), Validation (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorJ.-F. Nicolas, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), Methodology (equal), Project administration (equal), Resources (equal), Supervision (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorE. Decullier, Hospices Civils de Lyon, Public Health Department, Lyon, France Claude Bernard University Lyon I, Lyon, France Contribution: Formal analysis (lead)Search for more papers by this authorA. Nosbaum, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), Methodology (equal), Project administration (equal), Resources (equal), Supervision (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorF. Bérard, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), ​Investigation (equal), Methodology (equal), Project administration (lead), Resources (equal), Supervision (lead), Validation (equal), Visualization (equal), Writing - original draft (lead), Writing - review & editing (lead)Search for more papers by this author J. Castagna, Corresponding Author castagnajulie@gmail.com orcid.org/0000-0002-9983-9521 Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Contribution: Conceptualization (lead), Data curation (lead), Methodology (lead), Resources (equal), Writing - original draft (lead), Writing - review & editing (lead)Search for more papers by this authorL. Bernard, Hospices Civils de Lyon, Public Health Department, Lyon, France Claude Bernard University Lyon I, Lyon, France Contribution: Formal analysis (lead)Search for more papers by this authorF. Hacard, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Resources (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorF. Delcroix, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Resources (equal), Validation (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorA.-S. Darrigade, Department of Dermatology, Bordeaux University Hospitals, Bordeaux, France Contribution: Resources (equal), Validation (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorJ.-F. Nicolas, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), Methodology (equal), Project administration (equal), Resources (equal), Supervision (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorE. Decullier, Hospices Civils de Lyon, Public Health Department, Lyon, France Claude Bernard University Lyon I, Lyon, France Contribution: Formal analysis (lead)Search for more papers by this authorA. Nosbaum, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), Methodology (equal), Project administration (equal), Resources (equal), Supervision (equal), Validation (equal), Visualization (equal), Writing - original draft (equal), Writing - review & editing (equal)Search for more papers by this authorF. Bérard, Hospices Civils de Lyon, Clinical Immunology and Allergology, Pierre-Bénite, France Claude Bernard University Lyon I, Lyon, France Contribution: Conceptualization (equal), ​Investigation (equal), Methodology (equal), Project administration (lead), Resources (equal), Supervision (lead), Validation (equal), Visualization (equal), Writing - original draft (lead), Writing - review & editing (lead)Search for more papers by this author First published: 12 June 2020 https://doi.org/10.1111/bjd.19312Citations: 3 Funding sources: none. Conflicts of interest: A.N. has received investigator grants, lecturer honoraria or consulting payments from Sanofi-Regeneron, Pierre Fabre, Janssen-Cilag, Celgene, Lilly, LEO Pharma, Galderma, AbbVie, Medac and Pfizer. F.B. received investigator grants, lecturer honoraria or consulting payments from Novartis. J.-F.N. received honoraria from Novartis. A.N. and F.B. contributed equally. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume183, Issue6December 2020Pages 1124-1126 RelatedInformation